

SOLID BIOSCIENCES INC.

CHARTER OF THE CLINICAL COMMITTEE OF THE BOARD OF DIRECTORS

PURPOSE

The purpose of the Clinical Committee (the “**Committee**”) of the Board of Directors (the “**Board**”) of **SOLID BIOSCIENCES INC.**, a Delaware corporation (the “**Company**”), shall be (i) to serve as a liaison/conduit between the Board and the Company’s Clinical and Regulatory staff to review and/or advise, as needed, on pertinent emerging clinical and regulatory-related questions and issues as may arise in the course of development, (ii) to advise on general clinical development and regulatory strategy and operational issues, (iii) to review and advise on recommendations to the Board regarding the Company’s clinical and regulatory strategies and opportunities, (iv) to perform such other functions as may be deemed necessary or convenient in efficiently carrying out the foregoing, and (v) to perform such other functions as the Board may from time to time assign to the Committee.

COMPOSITION

The Committee shall consist of at least two (2) members of the Board. No Committee member shall be an employee of the Company and each member shall be free from any relationship that would interfere with the exercise of his or her independent judgment, as determined by the Board, in accordance with the applicable independence requirement of The NASDAQ Stock Market LLC (“**NASDAQ**”), when and as required by NASDAQ. The members of the Committee shall be appointed by the Board upon the recommendation of the Nominating and Corporate Governance Committee. Vacancies on the Committee shall be filled by the Board. The chairman of the Committee (the “**Chairman**”) shall be appointed by the Board on the recommendation of the Committee, or if it does not do so, the Committee members shall elect a Chairman by vote of a majority of the full Committee. The Chairman (or in his or her absence, a member designated by the Chairman) shall preside at all meetings of the Committee. The Company’s Chief Medical Officer shall be the primary Company liaison to the Committee.

MEETINGS AND MINUTES

The Committee shall hold such regular or special meetings as its members deem necessary or appropriate, but in no event less than annually. The presence in person or by telephone of a majority of the Committee’s members shall constitute a quorum for any meeting of the Committee. All actions of the Committee will require (i) the vote of a majority of the members present at a meeting of the Committee at which a quorum is present or (ii) the unanimous written consent of the members of the Committee then serving. Minutes of each meeting, and each written consent, shall be prepared and distributed to each director of the

Company and the Secretary of the Company after each meeting and shall be placed in the Company's minute book.

AUTHORITY

The Committee shall have authority in its sole discretion to obtain, at the Company's expense, advice and assistance from internal or external scientific, medical, legal, accounting or other advisors and consultants. The Committee shall have full access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Committee to discharge his or her responsibilities hereunder.

The Committee may form and delegate authority to subcommittees as appropriate.

The approval of this charter by the Board shall be construed as a delegation of authority to the Committee with respect to the responsibilities set forth herein.

RESPONSIBILITIES

To implement the Committee's purposes and policies, the Committee shall be charged with the following duties and responsibilities outlined below. The Committee may supplement and, except as otherwise required by applicable law or the requirements of NASDAQ, deviate from these activities as it deems appropriate under the circumstances. The Committee will have the full power and authority to carry out the following primary responsibilities or to delegate such power and authority to one or more subcommittees of the Committee:

1. Provide strategic and/or operational clinical development and regulatory advice and make recommendations to management of the Company, as applicable, regarding current and planned research and development programs.
2. Provide strategic and/or operation clinical and regulatory advice and guidance to management of the Company, as applicable, regarding advancement of clinical studies or programs.
3. Advise the Board, as requested, regarding potential clinical and/or regulatory issues related to potential licensing and acquisition opportunities.
4. Through the Chairman, shall report all material activities of the Committee to the Board from time to time, or whenever so requested by the Board.
5. Review, discuss and assess its own performance at least annually, and shall report the results of such assessment to the Board.

Effective as of December 13, 2018